| |MARCH 20268AUROBINDO PHARMA UNIT IV CLEARS US FDA INSPECTION WITH VAIAurobindo Pharma has announced that the US FDA VAI classification has been granted to an API manufacturing facility operated by its wholly owned subsidiary, Apitoria Pharma Private Limited.The update follows a regulatory inspection by the U.S. Food and Drug Administration (US FDA) at the company's manufacturing site in Telangana.The inspection was conducted at the active pharmaceutical ingredient (API) facility located in Pashamylaram Village between December 9 and December 17, 2024. After reviewing the findings, the regulator categorized the inspection outcome as Voluntary Action Indicated (VAI), indicating that while certain observations were made, they do not require any immediate regulatory enforcement action.The US FDA VAI classification typically means that inspectors identified minor compliance issues during the inspection. However, these observations are not considered serious enough to trigger official regulatory measures such as warning letters or import restrictions. Instead, the company is expected to address the observations through voluntary corrective actions.Aurobindo Pharma said it has now received the Establishment Inspection Report (EIR) from the US regulator confirming the VAI status for the facility. The EIR formally closes the inspection process and signals that the regulator is satisfied with the overall compliance status of the manufacturing unit.The development is important for the company as regulatory compliance with the US FDA remains critical for Indian pharmaceutical firms that export medicines to the United States. Facilities that maintain acceptable inspection outcomes can continue supplying products to the global market without regulatory disruption.Investors and industry watchers will continue to track regulatory updates from Aurobindo Pharma's manufacturing network, as FDA inspection outcomes often influence operations, product approvals, and export momentum for pharmaceutical companies. POTOP STORIESINDIA BANS PROMOTION OF WEIGHT-LOSS DRUGS, WARNS PHARMA FIRMSCentral Drugs Standard Control Organisation (CDSCO) has directed pharmaceutical companies to immediately stop any direct or indirect promotion of weight-loss drugs, warning that violations could invite regulatory action.The country's drug regulator issued the advisory as demand for obesity treatments continues to grow and companies increasingly push these medicines through advertising and awareness campaigns.The regulator clarified that promotion of weight-loss drugs is not allowed in any form under existing drug advertising rules. This includes advertisements on television, print, digital platforms, and social media. The advisory also targets surrogate promotions, where companies indirectly market prescription medicines through disease awareness campaigns or influencer messaging that encourages people to seek specific treatments.According to the regulator, some campaigns have exaggerated the benefits of obesity medicines while downplaying the importance of lifestyle changes such as diet control and physical activity. Officials warned that such promotions can mislead consumers and create unnecessary demand for prescription drugs that should only be used under medical supervision.The directive comes at a time when global demand for obesity treatments, particularly GLP-1 based drugs, has surged. These medicines, originally developed to treat diabetes, are now widely used for weight management and have attracted significant interest from pharmaceutical companies looking to enter India's growing obesity drug market.CDSCO also cautioned companies against using doctors, influencers, or online platforms to indirectly recommend or promote prescription medicines for weight reduction. Any activity that pushes consumers toward a specific product or therapy may be treated as a violation of advertising rules.By tightening oversight, the drug regulator aims to prevent misleading promotions and ensure that weight-loss drugs are prescribed only when medically necessary and under proper clinical guidance. PO
< Page 7 | Page 9 >